News
-
Alveolus Bio, which is developing inhaled therapies for the treatment of respiratory diseases, announced that Indian API manufacturer and CDMO Shilpa Medicare Limited has led a strategic financing round that will fund Phase 2 development… Read more . . .
-
AeroRx Therapeutics announced that a Phase 2a trial of its AERO-007 indacaterol / glycopyrrolate inhalation solution demonstrated statistically significant improvements FEV1 versus placebo for both doses studied. According to the company, the inhalation solution is… Read more . . .
-
Rocket Science Health, which recently partnered with Kindeva on development of its nasal delivery device, announced that the US Patent and Trademark Office (USPTO) has issued the company US Patent No. 12,343,489, titled, “Intranasal and… Read more . . .
-
GSK has announced that it will pay $500 million to Hengrui Pharma up front for the rights to Hengrui’s HRS-9821, an inhaled dry powder PDE3/4 inhibitor for the treatment of COPD, plus options to license… Read more . . .
-
According to AstraZeneca, the EMA’s the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s LGWP version of Trixeo (Breztri) Aerosphere budesonide / glycopyrronium / formoterol MDI, which uses Honeywell’s Solstice… Read more . . .
-
Avalyn Pharma announced that it has closed a $100 million Series D financing, with proceeds intended to support continued development of its inhaled drugs for the treatment of pulmonary fibrosis, including AP01 pirfenidone, AP02 nintedanib,… Read more . . .
-
HCmed Innovations announced that the FDA has granted 510(k) clearance to the company’s AdheResp connected breath-actuated mesh nebulizer, which delivers aerosol during inhalation only. According to the company, AdheResp is the first nebulizer of its… Read more . . .
-
According to ARS Pharmaceuticals, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the company’s marketing application for EURneffy adrenaline nasal spray for the emergency treatment of anaphylaxis in patients who weigh more than 30… Read more . . .
-
BiomX announced that it has initiated a Phase 2b study of its BX004 inhaled phage cocktail cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX had said in November 2023 that it planned to advance… Read more . . .
-
Oragenics, which recently announced that it had raised approximately $16.5 million for Phase 2 development of its OPN-002 neurosteroid nasal powder for the treatment of mild traumatic brain injury, says that Sterling Pharma Services will… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK